PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to salvage CAR t failures in lymphoma
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs (CC-99282 and rituximab) in people with certain types of non-Hodgkin lymphoma whose cancer did not respond well to CAR T-cell therapy. The goal is to find the safest dose and see if the combo can help control the disease. Ab…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated May 26, 2026 05:52 UTC
-
New combo aims to boost CAR-T power against rare lymphoma
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has come back or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New CAR T-Cell therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called GF-CART01 for adults aged 18-70 with B-cell blood cancers (like certain lymphomas) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:50 UTC